Our Partners

All programmes in ImmBio's porfolio benefit from external grant support and are delivered working with collaborators possessing world-leading expertise. To date, ImmBio has received funding from a number of sources, including the UK Technology Strategy Board (TSB), Medical Research Council (MRC), Biosciences & Biotechnology Sciences Research Council (BBSRC), the European Union and the Bill & Melinda Gates Foundation.

ImmBio's lead PnuBioVax project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No.866570.


To date, ImmBio has also received funding from:

  •     UK Biomedical Catalyst, Technology Strategy Board (TSB)
  •     Bill & Melinda Gates Foundation
  •     DPFS, Medical Research Council, (MRC)
  •     Engineering & Physical Sciences Research Council (EPSRC)
  •     UK Biosciences & Biotechnology Sciences Research Council (BBSRC)
  •     Australian Research Council (ARC)

ImmBio's lead programme, the pneumococcal vaccine PnuBioVax™, was initiated with support from the UK Biomedical Catalyst and the Technology Strategy Board.

ImmBio has now entered into a research, co-development and end-product licensing agreement with the Chinese state vaccine organisation, CNBG, for the development of PnuBioVax as a pneumococcal disease vaccine in China.  


ImmBio's meningococcal vaccine programme, MenBioVax™, was developed pre-clinically in collaboration with the HPA and initiated with support from the MRC DPFS programme. 

For its TB vaccine T-BioVax, ImmBio has entered into a research, co-development and end-product licensing agreement with CNBG, the Chinese state vaccine organisation. Previously, the company’s TB research has been supported by The Bill & Melinda Gates Foundation via the Aeras Global TB Vaccine Foundation following PoC studies at the National Institute for Biological Standards and Control on the programme. 

ImmBio is working with Associate Prof. Phil Sutton at the University of Melbourne, Australia, studying the mechanism of action of ImmBioVax™, with support from the ARC.


ImmBio's viral vaccine programmes, ImmunoBodies™ involve collaborative projects with a number of academic centres of excellence.

The influenza programme involves collaborations with the Department of Pathology, University of Cambridge and the School of Microbiological Sciences at the University of Reading. The hepatitis project, including ex vivo patient studies, is conducted in association with Barts and the London School of Medicine and Dentistry, The Royal London Hospital. ImmBio has also worked with University College London, Advanced Centre for Biochemical Engineering, deploying Ultra Scale Down (USD) technology in process design.